SCHEDULE: Deep Track Capital Exits Tectonic Therapeutic Stake

Deep Track Capital and its affiliates have reported zero beneficial ownership in Tectonic Therapeutic, Inc., indicating a complete divestment of their prior stake.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
• As of September 30, 2025, the Reporting Persons beneficially own 0 shares of Tectonic Therapeutic, Inc.'s Common Stock.
• This represents 0% of the class of securities, down from a previously held position (implied by the amendment).
• The total Common Stock outstanding for Tectonic Therapeutic, Inc. was 18,712,128 shares as of August 1, 2025, according to the issuer's 10-Q filed on August 7, 2025.
• The Reporting Persons certify that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 3

Explanation: The complete divestment of shares by an institutional investor like Deep Track Capital is generally a negative signal, suggesting a loss of confidence or a strategic shift away from the issuer. While the filing itself is purely factual, the action it reports is unfavorable for the issuer's stock perception.

Negatives

• The complete divestment of shares by Deep Track Capital, a specialized biotechnology investor, could signal a loss of confidence in Tectonic Therapeutic, Inc.'s future prospects or a strategic reallocation of capital away from the company.

Future Outlook

No forward-looking statements or guidance regarding Tectonic Therapeutic, Inc.'s operations or financial performance are provided in this beneficial ownership report.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

A complete divestment by an institutional investor, especially one focused on biotechnology like Deep Track Capital, could signal a shift in investment strategy or a re-evaluation of the issuer's prospects within the competitive biotech industry. This action may prompt other investors to scrutinize Tectonic Therapeutic, Inc.'s fundamentals and market position.

Stakeholder Impact

• Shareholders: Existing shareholders might perceive the institutional divestment negatively, potentially leading to downward pressure on the stock price.
• Management: Management may face increased scrutiny and questions regarding the reasons for a significant institutional investor's complete exit.

Key Dates

Recommendation

The complete divestment of an institutional stake, particularly by a specialized fund like Deep Track Capital in biotechnology, signals a significant lack of confidence or a fundamental change in investment thesis regarding Tectonic Therapeutic, Inc. This action typically precedes or accompanies negative market sentiment and could lead to downward pressure on the stock. Investors should consider this a strong negative signal and evaluate exiting their position.

Keywords

Tectonic Therapeutic, Deep Track Capital, Schedule 13G, Beneficial Ownership, Divestment, Common Stock, Institutional Investor, SEC Filing